BA
VRTX icon

Bristlecone Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bristlecone Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,250
Closed -$1.09M – 377
2025
Q1 		$1.09M Buy
2,250
+100
+5% +$46.6K 0.09% 146
2024
Q4 		$866K Hold
2,150
– – 0.07% 157
2024
Q3 		$1,000K Hold
2,150
– – 0.08% 140
2024
Q2 		$1.01M Sell
2,150
-15
-0.7% -$6.51K 0.09% 140
2024
Q1 		$905K Buy
2,165
+115
+6% +$48.6K 0.08% 146
2023
Q4 		$834K Buy
2,050
+5
+0.2% +$1.85K 0.08% 148
2023
Q3 		$711K Sell
2,045
-56
-3% -$19.6K 0.08% 146
2023
Q2 		$739K Sell
2,101
-58
-3% -$19.5K 0.07% 149
2023
Q1 		$680K Sell
2,159
-326
-13% -$97.8K 0.07% 149
2022
Q4 		$718K Sell
2,485
-51
-2% -$15.5K 0.09% 145
2022
Q3 		$734K Sell
2,536
-29
-1% -$8.34K 0.1% 137
2022
Q2 		$723K Buy
2,565
+302
+13% +$80.8K 0.09% 138
2022
Q1 		$591K Buy
2,263
+24
+1% +$5.7K 0.07% 148
2021
Q4 		$492K Buy
2,239
+274
+14% +$53.3K 0.06% 167
2021
Q3 		$356K Buy
1,965
+410
+26% +$80K 0.05% 171
2021
Q2 		$314K Buy
1,555
+21
+1% +$4.39K 0.04% 178
2021
Q1 		$330K Buy
1,534
+171
+13% +$37.6K 0.05% 171
2020
Q4 		$322K Buy
+1,363
New +$313K 0.05% 169

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bristlecone Advisors's VRTX Position: Q2 2025 in Review

Bristlecone Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 2,250 shares — an estimated $1.09M sold.

Bristlecone Advisors first reported a position in VRTX in Q4 2020 and held it in 18 quarters. The position peaked at $1.09M in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Bristlecone Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bristlecone Advisors sold 2,250 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.09M.
  • Bristlecone Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 18 quarters.
  • Bristlecone Advisors's Vertex Pharmaceuticals position peaked at $1.09M in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Bristlecone Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.